BACKGROUND Inequalities in cervical cancer may be increased following mass vaccination against the human papillomavirus (HPV) if girls with low vaccine uptake also have low future participation in cervical cancer screening. We evaluated how vaccine uptake distribution affects inequalities in squamous cell carcinoma (SCC) incidence between groups with different screening participation. METHODS...

The choice of adjuvants is critical for any vaccine whether prophylactic or therapeutic. Our group previously showed that incomplete Freund’s adjuvant, commonly used in different cancer vaccine trials, had many undesirable effects on T cell trafficking and function which directly translates into poor anti-tumor efficacy in preclinical murine model. Switching from oil-based (IFA) to water based ...

Pancreatic cancer is one of the most aggressive and lethal human cancers, with more than 200, 000 deaths worldwide every year. Despite recent efforts, conventional treatment approaches, such as surgery, classic chemotherapy, radiotherapy, biologic therapy and palliative care have only slightly improved patient outcomes. Among the conventional chemotherapies the combination of abraxane (nab-pacl...

The main target group for vaccination against human papillomavirus (HPV), the sexually transmitted virus that causes cervical cancer, will be young adolescents. We undertook a population-based survey to assess parental consent and potential HPV vaccine uptake in eight secondary schools using stratified randomisation according to school type and ethnicity. Our results suggest that in socially an...

Patients with active cancer (cancer on treatment, those planning to start and immediately post-treatment) consider getting the COVID-19 vaccine, like other vulnerable populations, reduce severe risk of SARS-CoV-2 infection. We suggest patients should be vaccinated a non-lived vaccine. Specific consideration belongs type cancer, current phase disease along continuum, optimal timing for vaccinati...

Antigenic differences between normal and malignant cells of the cancer patient form the rationale for clinical immunotherapeutic strategies. Because the antigenic phenotype of neoplastic cells varies widely among different cells within the same malignant cell-population, immunization with a vaccine that stimulates immunity to the broad array of tumor antigens expressed by the cancer cells is li...